How have IN shares performed in 2024?

InMed Pharmaceuticals' stock was trading at C$4.19 at the start of the year. Since then, IN stock has increased by 0.0% and is now trading at C$4.19. View the best growth stocks for 2024 here .

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI) , Aurora Cannabis (ACB) , Canopy Growth (WEED) , Baidu (BIDU) , Cara Therapeutics (CARA) , Copper Mountain Mining (CMMC) , Corbus Pharmaceuticals (CRBP) , HEXO (HEXO) , InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU) .

How do I buy shares of InMed Pharmaceuticals?

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:IN

InMed Pharmaceuticals (IN) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free IN Stock Alerts

C$4.19

-0.07 (-1.64%)

(As of 05/7/2021)

Compare

Today's Range: C$4.13
▼
C$4.27
50-Day Range: C$4.19
▼
C$4.19
52-Week Range: C$3.35
▼
C$13.86

Volume: 17,035 shs
Average Volume: 29,552 shs
Market Capitalization: C$33.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get InMed Pharmaceuticals alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About InMed Pharmaceuticals Stock (TSE:IN)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

IN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IN Stock News Headlines

April 9, 2024 | americanbankingnews.com

InMed Pharmaceuticals (TSE:IN) Trading Down 1.6%

April 6, 2024 | theglobeandmail.com

InMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

February 13, 2024 | finanznachrichten.de

InMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

February 13, 2024 | finance.yahoo.com

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

January 22, 2024 | theglobeandmail.com

InMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

January 16, 2024 | finance.yahoo.com

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

December 12, 2023 | finance.yahoo.com

InMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid Analog

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

November 30, 2023 | theglobeandmail.com

InMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration

November 29, 2023 | finance.yahoo.com

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

November 14, 2023 | msn.com

InMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8M

October 24, 2023 | finance.yahoo.com

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 13, 2023 | benzinga.com

Cannabis Industry Report Highlights Positive Sentiment and Growth Potential at Benzinga Conference

August 11, 2023 | finanznachrichten.de

DelveInsight Business Research, LLP: Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsight

July 20, 2023 | finance.yahoo.com

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 7, 2023 | msn.com

Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise

April 25, 2023 | marketwatch.com

Biosynthesis of Cannabinoids Market Growth By 2030

April 20, 2023 | marketwatch.com

Blepharitis-Pipeline Market Description and Business Overview By 2030

March 27, 2023 | benzinga.com

InMed Pharmaceuticals: Pushing Pharma Forward With Rare Cannabinoids

March 17, 2023 | benzinga.com

Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023

March 13, 2023 | finance.yahoo.com

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

February 21, 2023 | benzinga.com

InMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?

February 20, 2023 | marketwatch.com

Epidermolysis Bullosa Market is Booming in Near Future 2023-2028 with Top Countries Data

February 20, 2023 | finanznachrichten.de

InMed Pharmaceuticals Inc.: InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023 | yahoo.com

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023 | msn.com

InMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47M

See More Headlines

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: TSE:IN
CUSIP: N/A
CIK: N/A
Web: www.inmedpharma.com
Phone: 604-669-7207
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 8.48
Current Ratio: 2.13
Quick Ratio: 1.45

Sales & Book Value

Annual Sales: C$574,677.00
Price / Sales: 58.70
Cash Flow: C$0.40 per share
Price / Cash Flow: 10.40
Book Value: C$0.76 per share
Price / Book: 5.50

Miscellaneous

Outstanding Shares: 8,051,000
Free Float: N/A
Market Cap: C$33.73 million
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Eric A. Adams (Age 58)
Pres, CEO & Director
Comp: $488.44k
Ms. Alexandra Diane-Janet Mancini (Age 69)
Sr. VP of Clinical & Regulatory Affairs
Comp: $337.13k
Dr. Sazzad Hossain M.Sc. (Age 64)
Ph.D., Co-Founder
Ms. Brenda Edwards C.M.A.
CPA, Interim Chief Financial Officer
Mr. Michael Woudenberg P.Eng. (Age 55)
Chief Operating Officer
Colin Clancy
Sr. Director of Investor Relations
Mr. Jerry P. Griffin
VP of Sales & Marketing
Dr. Eric Chih-Hsien Hsu (Age 52)
Sr. VP of Preclinical R&D
Dr. Shane A. Johnson Ph.D.
Sr. VP & GM of BayMedica
Dr. Ado Muhammad
Sr. Consultant of Medical Affairs

Key Competitors

View All Competitors

Insiders

Eric Ashley Adams
Bought 41,600 shares on 2/20/2024
Total: C$14,921.92 ($0.36/share)

IN Stock Analysis - Frequently Asked Questions

How have IN shares performed in 2024?: InMed Pharmaceuticals' stock was trading at C$4.19 at the start of the year. Since then, IN stock has increased by 0.0% and is now trading at C$4.19.
View the best growth stocks for 2024 here.
What other stocks do shareholders of InMed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).
How do I buy shares of InMed Pharmaceuticals?: Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:IN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

InMed Pharmaceuticals (IN) Stock Price, News & Analysis

About InMed Pharmaceuticals Stock (TSE:IN)

IN Stock Price History

IN Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

IN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info